Floatz Rating
B60/100
Confidence
Indicative
Sponsor
CHU de Quebec-Universite Laval
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05896371CT.gov A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy | — | Not Yet Recruiting | — | — | — |
NCT05521412CT.gov EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T | — | Recruiting | — | — | — |
NCT05383079CT.gov Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT05204927CT.gov 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT04188587CT.gov 177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Psma I&T (this asset) | CHU de Quebec-Universite Laval | P3 | B · 60 |
| AXUMIN | VA Greater Los Angeles Healthcare System | P4 | BBB |
| Leuporelin | Mayo Clinic | P4 | BBB |
| Prednisone | Mayo Clinic | P4 | BB |
| Abiraterone | Mayo Clinic | P4 | BB |
| Pembrolizumab | CuraCell TX AB | P2 | BB |
| Degarelix | Praful Ravi, MB BCHir, MRCP | P3 | BB |
| Sipuleucel-T | Yale University | P2 | BB |
| Cabazitaxel | AstraZeneca | P4 | BB |
+42 more in the Metastatic Prostate Carcinoma cohort
Other indications for Psma I&T
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Cancer | — | P2 | CCC · 54 |
| Nonpapillary Renal Cell Carcinoma | — | P1/2 | CCC · 52 |
| Metastatic Malignant Neoplasm | — | P1/2 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Psma I&T in Metastatic Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/psma-it-metastatic-prostate-carcinoma-120844
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →